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Background: In animals, low levels of vitamin D are associated with estrus cycle disturbances, but there are virtually no
human data. We examined the association of 25-hydroxyvitamin D (25(OH)D) (a biomarker for vitamin D status) with
menstrual cycle characteristics.
Methods: Women aged 35-44 were randomly selected from a Washington D.C. health plan and invited to participate
in the Uterine Fibroid Study (1996 – 1999). Our analysis includes 636 women (57% were African-American) who
provided a blood sample and completed a telephone interview that included gynecologic history. Women were asked
their usual cycle length in the preceding year. Women who reported it was “too irregular to estimate” were classified
as having irregular cycles (N = 48). Women were excluded if they currently or recently used hormonal contraception
or any other medication that influences menstrual cycles. 25(OH)D was measured by radioimmunoassay in stored
plasma samples.
Results: The median 25(OH)D level was 12.0 ng/mL (interquartile range: 7.6, 19.7 ng/mL). After controlling for age, race,
BMI, education, age of menarche, current smoking, alcohol use, and physical activity, a decrease in 25(OH)D of 10 ng/mL
was associated with 1.9 times the odds of irregular cycles (Odds ratio (OR) (95% confidence interval (CI)): 1.9 (1.0, 3.4),
p = 0.04). 25(OH)D was not associated with the occurrence of short cycles (OR(CI): 1.08 (0.79, 1.48, p = 0.6) or long cycles
(OR(CI): 1.31 (0.66, 2.60), p = 0.4).
Conclusions: Lower levels of 25(OH)D were associated with irregular cycles, but not with short or long cycles. Vitamin D
may play a role in regulating ovulatory function. Further investigation of potential mechanisms is warranted.
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Vitamin D is known for its role in bone health [1], but
its role in reproduction is a new, active area of investiga-
tion [2-4]. Vitamin D receptor is expressed in the ovary,
placenta, and the uterus [2-4]. Lower vitamin D has
been related to premenstrual syndrome, uterine fibroids,
dysmenorrhea and early menarche [4,5].
Diet-induced vitamin D deficiency causes dramatically
reduced fertility in both rats and mice, with a 45-70%
reduction in the probability of becoming pregnant and a
67-100% reduction in the number of viable pups [2].* Correspondence: jukica@niehs.nih.gov
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unless otherwise stated.Knock-out mice missing the enzyme for converting vita-
min D to its active form show estrus cycle disturbances in-
cluding arrested follicular development, prolonged estrous
cycles, and anovulation [6,7].
The promoter region for the gene encoding anti-
Müllerian hormone (AMH) contains a domain for the
vitamin D response element, suggesting that vitamin D
can regulate AMH expression [8]. AMH in turn regu-
lates follicular recruitment, which provides a mechanism
for vitamin D to influence ovarian function and men-
strual cycle regularity [4]. However, population-based
human data regarding vitamin D and menstrual cycles
are lacking.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vitamin D with menstrual cycle characteristics including
long and short cycle length and cycle regularity in a




The National Institute of Environmental Health Sciences
(NIEHS) Uterine Fibroid Study, 1996 – 1999, enrolled par-
ticipants identified from a large health plan in Washington,
DC [5,9,10]. In short, randomly selected health plan mem-
bers between the ages of 30 and 49 were contacted and
80% of those eligible participated (N = 1430). Women
completed a telephone administered questionnaire that in-
cluded reproductive and gynecologic history data. Women
were invited to the primary care site for an in-person
study visit that included a blood draw. Blood samples were
processed and stored at -80°C. For this study, we excluded
surgically and naturally menopausal women (N = 189),
women who may have used hormonal contraception
(N = 102), and women who were not naturally cycling over
the index year (N = 53). To further ensure the exclusion of
women who were peri-menopausal, we excluded women
45 or over (N = 340). This left 746 women.Figure 1 Flowchart depicting the number of women in the Uterine Fi
cycle length.All of the women provided informed consent and the
study protocol was approved by the NIEHS institutional
review board.
Vitamin D measurement
Vitamin D status was quantified through the measure-
ment of the circulating metabolite 25-hydroxyvitamin D
(25(OH)D) in stored plasma samples. 25(OH)D is a
widely accepted biomarker for vitamin D [11]. 25(OH)D
was measured by radioimmunoassay [12] with a method
developed at a laboratory that has been certified by the
international Vitamin D External Quality Assessment
Scheme, and had been for over 10 years. The antibody
was generated by the lab, and was co-specific for both
25(OH)D2 and 25(OH)D3. The intra- and interassay co-
efficients of variation based on blind replicates were
7.6% and 10.6%, respectively. One hundred and four
women were missing a 25(OH)D measurement, mostly
due to a lack of available blood sample, leaving 642
(Figure 1).
Menstrual cycle characteristics
Women were asked to report their menstrual cycle
length in the preceding year. Lower 25(OH)D is hypo-
thesized to interfere with normal follicular development,broid Study included in the analysis of 25(OH)D and menstrual
Table 1 Characteristics of participants from the Uterine
Fibroid Study included in the menstrual cycle characteristics
analysis (N = 636), Washington D.C. (1996 – 1999)
N (%) 25(OH)D mean (SD)
25(OH)D
≤20 ng/mL 484 (76) - -
>20 ng/mL 152 (24) - -
Irregular cycles
No 588 (92) 14.3 (8.3)
Yes 48 (8) 10.4 (6.1)
Short cycles (17 – 25 days)
No 453 (71) 14.7 (8.4)
Yes 135 (29) 13.1 (7.9)
Long cycles (32 – 56 days)
No 566 (89) 14.3 (8.3)
Yes 22 (11) 16.3 (9.4)
Age
35 - 39 310 (49) 14.4 (8.3)
40 - 44 326 (51) 13.7 (8.1)
Race
White 216 (34) 20.5 (8.1)
African-American 369 (58) 10.1 (5.8)
Other 51 (8) 15.3 (5.7)
Education
Lest than a college degree 311 (49) 11.0 (6.5)
College graduate or more 319 (50) 17.0 (8.7)
Missing 6 (0.9)
Body mass index
<25 kg/m2 258 (41) 17.6 (9.0)
25 - < 30 170 (27) 13.7 (7.5)
30 - <40 159 (25) 10.2 (5.7)
≥40 49 (8) 9.0 (4.5)
Smoker
Non-smoker 490 (77) 14.8 (8.4)
Current smoker 146 (23) 11.6 (7.1)
Alcohol (drinks per week)
0 120 (19) 10.6 (6.1)
>0 - 1 188 (30) 13.3 (7.4)
>1 – 7 211 (33) 16.2 (8.5)
>7 79 (12) 15.3 (10.0)
Missing 40 (6)
Vigorous physical activity
0 – 1.8 MET-hours/weeka 203 (32) 11.9 (7.2)
>1.8 – 4.1 203 (32) 14.2 (8.1)
Table 1 Characteristics of participants from the Uterine
Fibroid Study included in the menstrual cycle characteristics
analysis (N = 636), Washington D.C. (1996 – 1999)
(Continued)
>4.1 – 6.5 108 (17) 15.0 (8.5)
>6.5 – 24.3 121 (19) 16.6 (8.9)
Missing 1 (0.2)
Age at menarche
<11 years 51 (8) 12.4 (7.1)
11 - 14 506 (80) 14.3 (8.2)
>14 years 77 (12) 13.4 (8.9)
Missing 2 (0.3)
aMET =Metabolic equivalents.
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strual cycles (a combination of normal, short, and long
cycles). To investigate this, we separated women into
four categories of cycle length: short, long, normal, or
irregular. Women who reported that their cycle length
was “too irregular to estimate,” and thus could not
choose one number to describe their usual cycle length,
were classified as having irregular cycles (N = 48).
Women who did not report irregular cycles were classi-
fied as having “short” cycles if their usual cycle length
was 17 - 25 days. We defined “long” cycles as 32-56
days. Given the natural decrease in cycle length among
older women, the expected rarity of cycles greater than
35 days [13], and the rarity in our study population, we
considered “long” cycles to occur at 32 days or more.
The reference category was 26 to 31 days. Four women
did not answer the cycle length question and 2 women
reported a cycle length of 15 days or less. These women
were excluded from the analyses of irregular cycles or
cycle length, leaving 636 women (Figure 1).
Covariates
Data on covariates were collected through self-administered
and telephone questionnaires. Body weight was mea-
sured at the clinic visit. Potential confounders consi-
dered included: age, education, race, body mass index
(BMI), alcohol intake, current cigarette smoking, phy-
sical activity, and age at menarche.
Statistical analysis
25(OH)D was structured both as a continuous linear
variable and as a dichotomous variable of “insufficient”
versus “sufficient” based on the Institute of Medicine
cutpoint of 20 ng/mL [14]. Associations between
25(OH)D and short, long and irregular cycles were
estimated through multivariable polytomous (also called
multinomial) logistic regression to adjust for potential
confounders. This models the association between the
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length categories simultaneously [15]. The regression
coefficient from the linear fit to 25(OH)D was multiplied
by -10 and then exponentiated to represent the odds of
each cycle type for a 10 ng/mL decrease in 25(OH)D.
Women who reported regular cycles with a usual cycle
length 26 to 31 days served as the referent group. We
examined two different adjustment sets. In the first
model (“Model 1”), the analysis of 25(OH)D and short,
long and irregular cycles was minimally adjusted for age
(linear) and race. A second model (“Model 2”) is also
presented including adjustment for age and race and in
addition, BMI (in four categories), education (dichotom-
ous), alcohol intake (four categories), age of menarche
(three categories), current smoking (yes/no), and phy-
sical activity (four categories of metabolic equivalent-
hours per week). The categories of each covariate are
shown in Table 1. An interaction term between 25(OH)D
and race was tested in model 2, and was not significant
(p = 0.30). We therefore present our results adjusted for
race, but not stratified.
Results
Eight percent of study participants reported having irregu-
lar cycles, 29% were classified as having short cycles and
11% had long cycles (Table 1). The majority of women
were of African-American race and a little over half had at
least a college degree. Almost 60% of the women were
overweight or obese. The mean 25(OH)D level was
14.0 ng/mL (standard deviation: 8.2), with a median of
12.0 ng/mL (interquartile range: 7.6, 19.7 ng/mL). Most of
the women (76%) had insufficient vitamin D concentra-
tions (25(OH)D level below 20 ng/mL).
Lower levels of 25(OH)D were not associated with
short or long cycles (Table 2). The overall adjusted as-
sociation between 25(OH)D and cycle characteristic
category, treated as a four-category outcome (typicalTable 2 Associations of 25-hydroxyvitamin D (25(OH)D) with
Uterine Fibroid Study
N Model 1a OR (CI) per 10 ng/mL
decrease in 25(OH)D
Short cycles (≤25 days) 135 1.10 (0.82, 1.49)
Long cycles (≥32 days) 22 1.28 (0.69, 2.38)
Irregular cycles 48 2.17 (1.23, 3.83)
Model 1a OR(CI) for insufficient
versus sufficient 25(OH)D
Short cycles (≤25 days) 135 1.01 (0.60, 1.72)
Long cycles (≥32 days) 22 1.07 (0.40, 2.84)
Irregular cycles 48 3.09 (1.02, 9.42)
aResults of the polytomous logistic regression model adjusted for age (linear) and r
and a usual cycle length between 26 and 31 days (N = 431).
bResults of the polytomous logistic regression model adjusted for: age, race, BMI, ed
The referent category is women who reported regular menstrual cycles and a usualcycle length, short, long, irregular) was non-significant
by a 3 degree-of-freedom likelihood ratio test (p = 0.20).
However, in the fully adjusted model, a decrease in
25(OH)D of 10 ng/mL was associated with 1.9 times the
odds of having irregular menstrual cycles (Odds ratio
(OR) (95% Confidence Interval (CI)): 1.9 (1.0, 3.4),
p = 0.04) (Table 2, Model 2). Women who were below
the Institute of Medicine recommendation of 20 ng/mL
of 25(OH)D had almost two and a half times the odds of
having irregular menstrual cycles compared with women
who were above 20 ng/mL (OR(CI): 2.4 (0.8, 7.7),
p = 0.13). Despite our age restrictions and the self-
reported premenopausal status, it is possible that there are
perimenopausal women in our sample. To further investi-
gate this, we conducted a sensitivity analysis excluding
women who reported taking hormones for menopausal
symptoms (N = 5), this did not substantially alter the
association between 25(OH)D and irregular cycles (per
10 ng/ml decrease in 25(OH)D, OR(CI): 2.0 (1.1, 3.8),
p = 0.03). It is possible that having an intrauterine device
(IUD) would affect a participant’s menstrual cycle pat-
terns, though none were using an hormonal IUD. Ex-
cluding women with an IUD (N = 14) did not change the
estimates (OR(CI): 1.8 (1.0, 3.4), p = 0.05). Excluding
women who reported a thyroid disorder did not alter the
adjusted estimate (OR(CI): 1.8 (1.0, 3.4)). Twenty-seven
women reported a pregnancy in the year prior to
interview (N = 15 miscarriages and N = 11 live births)
but had menstrual periods at the time of the in-
terview. Also, 28 women reported that they were on
medication that regulated their menstrual cycles for
“some” of the previous year. We performed a sensi-
tivity analysis excluding these 55 women and saw no
difference in the association (OR(CI): 1.9 (1.0, 3.6)).
Finally, excluding the one woman who used fertility
treatments in the last year (but was never pregnant)
did not alter the estimates.menstrual cycle characteristics among women from the
p-value N Model 2b OR (CI), per 10 ng/ml
decrease in 25(OH)D
p-value
0.51 133 1.08 (0.79, 1.48) 0.64
0.43 22 1.31 (0.66, 2.60) 0.44
0.008 46 1.87 (1.03, 3.39) 0.04
Model 2b OR(CI) for insufficient
versus sufficient 25(OH)D
0.96 133 0.95 (0.55, 1.67) 0.87
0.89 22 1.02 (0.35, 2.96) 0.97
0.05 46 2.44 (0.77, 7.69) 0.13
ace. The referent category is women who reported regular menstrual cycles
ucation, age of menarche, current smoking, alcohol use, and physical activity.
cycle length between 26 and 31 days (N = 426).
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cystic ovary syndrome (PCOS). These women tended to
have lower 25(OH)D levels (Mean: 6.6 ng/mL vs.
14.1 ng/mL) and the 25(OH)D level for all 6 women was
less than 20 ng/ml. It is unclear whether the biology
underlying the association of 25(OH)D with PCOS is re-
flective of the underlying biology that occurs in women
without PCOS. Thus, as a sensitivity analysis, we ex-
cluded women with PCOS, however the estimated asso-
ciation was unchanged (OR(CI): 1.8 (1.0, 3.3), p = 0.05).
Discussion
Lower plasma levels of 25(OH)D were associated with
an increased odds of having irregular cycles. Plasma
25(OH)D was not associated with the occurrence of
long or short menstrual cycles.
25(OH)D is converted to its active form 1,25(OH)D by
the enzyme 1α-hydroxylase, coded by the CYP27B1
gene. Cyp27b1 null mice and mice that lack the vitamin
D receptor have shown hypogonadism, arrested follicular
development, prolonged estrous cycles, and hypoplastic
uteri [6,7,16,17]. It is unclear whether the reproductive
phenotypes in these studies are the result of defects in
the ovarian response to gonadotropins or suboptimal
gonadotropin secretion from the pituitary or hypotha-
lamus [6]. In Cyp27b1 null mice the effect of vitamin D
deficiency was reversible, with estrous cycle length and
staging normalized with dietary supplementation with
vitamin D3 [6]. Moreover, in this murine model the
reproductive effects of vitamin D deficiency appear to
occur independent of calcium levels, although this is not
conclusive [6,18]. The promoter region for the gene
encoding anti-Müllerian hormone (AMH) contains a
domain for the vitamin D response element, suggesting
that vitamin D can regulate AMH expression [8]. AMH
in turn regulates follicular recruitment, which provides
some physiological plausibility for vitamin D to influence
ovarian function and possibly menstrual cycle regularity
[4]. Serum 25(OH)D has been inversely associated with
insulin resistance and hyperandrogenism in women
with PCOS [4]. Moreover, among women with PCOS,
supplementation with vitamin D has been reported to
normalize menstrual cycles and improve ovarian follicu-
logenesis and ovulation [19,20].
Our study is the first to examine the association of
vitamin D with menstrual cycle length in a population-
based sample of late reproductive-aged women. This
analysis is limited by the use of self-reported cycle length
and by small numbers of women with extreme cycle
lengths, particularly long cycles and irregular cycles.
Most of the women in this study had insufficient
25(OH)D levels which, combined with small numbers of
irregular cycles, reduced the power to detect an asso-
ciation between the dichotomous 25(OH)D exposure(≤20 ng/ml vs >20 ng/ml) and irregular cycles. This
study is based on a cross-sectional design, with women
reporting their typical cycle length for the past year at
the time of blood collection. It is possible that some of
the women in our analysis had undiagnosed PCOS. We
did not have other hormonal or clinical markers of
PCOS in this sample. Subclinical PCOS might be an
underlying factor (or intermediate) in the association of
25(OH)D with irregular cycles.
Conclusions
We found that lower levels of 25(OH)D were associated
with irregular menstrual cycles in a population-based
sample of late reproductive-aged women. Vitamin D
may influence cycle regularity through its associations
with AMH, insulin, androgens, or a yet to be identified
pathway. Further investigation of potential mechanisms
is warranted.
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